title: A role for L-glutamate ionotropic receptors in the development of rat neurogenic pulmonary edema.
abstract: The present study was undertaken to evaluate possible roles of L-glutamate ionotropic receptors in neurogenic pulmonary edema. Perfusion of L-glutamate into the fourth ventricles of rats increased nitric oxide (NO) signals in the efflux solution concentration-dependently, significantly reducing both the occurrence and severity of neurogenic pulmonary edema. This effect was completely reversed by prior intracisternal injection of an NO synthase inhibitor, N(omega)-nitro-L-arginine methyl ester (L-NAME), or an N-methyl-D-aspartate (NMDA) receptor antagonist, dizocilpine maleate (MK-801), and partially by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), a 2-amino-3-hydroxy-5-methyl-4-isoxazol propionic acid (AMPA)/kainic acid receptor antagonist. Administration of MK-801 or CNQX alone, without L-glutamate, almost completely prevented neurogenic pulmonary edema development. These results suggest that endogenous L-glutamate may facilitate underlining disease process, whereas L-glutamate exogenously applied into the fourth ventricle may have an inhibitory action via release of NO, through ionotropic receptors.
authors.affiliation: Department of Anesthesiology, Nagoya University School of Medicine, Showa-ku, Nagoya 466-8550, Japan.
authors.forename: Hiroko
authors.initials: H
authors.lastname: Kondo
authors.forename: Guo-Gang
authors.initials: GG
authors.lastname: Feng
authors.forename: Kimitoshi
authors.initials: K
authors.lastname: Nishiwaki
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Shimada
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Hirokawa
authors.forename: Toru
authors.initials: T
authors.lastname: Komatsu
authors.forename: Takashi
authors.initials: T
authors.lastname: Yokochi
authors.forename: Naohisa
authors.initials: N
authors.lastname: Ishikawa
mesh_terms: D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001798:Blood Proteins / Q000378:metabolism; D001826:Body Fluids / Q000378:metabolism; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005337:Fibrin / Q000008:administration & dosage / Q000633:toxicity; D020546:Fourth Ventricle / Q000187:drug effects / Q000503:physiopathology; D018698:Glutamic Acid / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D016202:N-Methylaspartate / Q000494:pharmacology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism; D011506:Proteins / Q000378:metabolism; D011654:Pulmonary Edema / Q000139:chemically induced / Q000503:physiopathology* / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D017470:Receptors, Glutamate / Q000502:physiology*; D014630:Vagus Nerve / Q000503:physiopathology
chemical_list: D001798:Blood Proteins; D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D011506:Proteins; D017470:Receptors, Glutamate; D009569:Nitric Oxide; D018698:Glutamic Acid; D016202:N-Methylaspartate; D016291:Dizocilpine Maleate; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D005337:Fibrin; D019331:NG-Nitroarginine Methyl Ester